Non-enzymatic glycation reduces heparin cofactor II anti-thrombin activity

A. Ceriello, E. Marchi, M. Barbanti, M. R. Milani, D. Giugliano, A. Quatraro, P. Lefebvre

Research output: Contribution to journalArticlepeer-review


The effects of non-enzymatic glycation on heparin cofactor II activity, at glucose concentrations which might be expected in physiological or diabetic conditions have been evaluated in this study. Radiolabelled glucose incorporation was associated with a loss of heparin cofactor anti-thrombin activity. The heparin cofactor heparin and dermatan sulfatedependent inhibition of thrombin was significantly reduced, showing a remarkable decrease of the maximum second order rate constant. This study shows that heparin cofactor can be glycated at glucose concentrations found in the blood, and that this phenomenon produces a loss of heparin cofactor-antithrombin activity. These data suggest, furthermore, a possible link between heparin cofactor glycation and the pathogenesis of thrombosis in diabetes mellitus.

Original languageEnglish
Pages (from-to)205-207
Number of pages3
Issue number4
Publication statusPublished - Apr 1990


  • anti-thrombin activity
  • dermatan-sulfate
  • glycation
  • heparin
  • Heparin cofactor II

ASJC Scopus subject areas

  • Internal Medicine
  • Endocrinology, Diabetes and Metabolism


Dive into the research topics of 'Non-enzymatic glycation reduces heparin cofactor II anti-thrombin activity'. Together they form a unique fingerprint.

Cite this